Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.55 |
| ▸ | HTR6 | P50406 | 9/20 | 0.51 |
| ▸ | HRH1 | P35367 | 7/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293775 | 0.93 | HTR6 (0.47) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12820288 | 0.92 | GRIN2B (0.46) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17590175 | 0.88 | GRIN2B (0.55) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2186326 | 0.88 | HTR6 (0.66) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3235730 | 0.85 | HTR6 (0.56) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1120654 | 0.82 | HTR6 (0.55) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14326090 | 0.81 | HTR6 (0.64) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL1120760 | 0.81 | HTR6 (0.54) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL169178 | 0.81 | HRH1 (0.49) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2187697 | 0.81 | HTR6 (0.64) | HTR6HRH1BCHEHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | claimed |
| CN-102480955-A | Pyrido [4,3-b ] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2012-05-30 | — | — | CN | claimed |
| EP-2424364-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9255094-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255094-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| CN-102480955-A | Pyrido [4,3-b ] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2012-05-30 | — | — | CN | disclosed |
| EP-2424364-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GRIN2B 25/4885GRIN2D 36/4885GRIN3B 32/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | GRIN2B 242/4885GRIN2D 1104/4885GRIN3B 447/4885 |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GRIN2B 25/4885GRIN2D 36/4885GRIN3B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.